Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase.
Level 5 - mechanism / opinion, no new human data
In vitro recombinant enzyme and structure-activity relationship bench study with no human subjects
PubMed 40263713 · doi:10.1021/acs.jmedchem.5c00586
What was done
Researchers evaluated the inhibitory activity of clinically used hypoxia-inducible factor-α prolyl residue hydroxylase (PHD) inhibitors—Desidustat, Enarodustat, and Vadadustat—against isolated recombinant human γ-butyrobetaine hydroxylase (BBOX). They performed structure-activity relationship (SAR) studies on the Desidustat chemical scaffold to develop derivative compounds and tested their selectivity against BBOX relative to other representative human 2-oxoglutarate (2OG) oxygenases, including PHD2.
What was found
The abstract reports no numerical values (such as IC50, Ki, or selectivity ratios). Desidustat, Enarodustat, and Vadadustat each inhibited isolated recombinant BBOX in vitro. SAR optimization of the Desidustat scaffold produced potent derivatives demonstrating high selectivity for BBOX over other tested 2OG oxygenases, including PHD2.
Why it matters
This identifies BBOX inhibition as a possible off-target mechanism of action for clinically approved PHD inhibitors. It also establishes a new class of selective BBOX inhibitor tool compounds for investigating l-carnitine biosynthesis modulation.
Limits
The study is entirely in vitro using recombinant enzymes; no cellular, animal, or human pharmacokinetic and safety data are reported in the abstract. The abstract provides no quantitative metrics regarding potency or selectivity thresholds.
Cited by
- supports GBB (gamma-butyrobetaine) is the biochemical precursor to L-carnitine.